Effects of CB2 and TRPV1 Stimulation on Osteoclast Overactivity Induced by Iron in Pediatric Inflammatory Bowel Disease
暂无分享,去创建一个
A. Di Paola | E. Miele | C. Strisciuglio | M. Martinelli | F. Rossi | C. Tortora | M. Argenziano | M. Creoli
[1] Zizhen Zhang,et al. Gut-innervating TRPV1+ Neurons Drive Chronic Visceral Pain via Microglial P2Y12 Receptor , 2021, Cellular and molecular gastroenterology and hepatology.
[2] V. Rizzo,et al. Cannabis and Its Potential Protective Role Against Inflammatory Bowel Disease: A Scoping Review , 2021, Cureus.
[3] Paweł Kuźnicki,et al. Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse , 2021, Journal of clinical medicine.
[4] A. Swaminath,et al. Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians , 2021, Advances in Therapy.
[5] E. Pac-Kożuchowska,et al. Interleukin 6: biological significance and role in inflammatory bowel diseases. , 2021, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[6] N. Chattipakorn,et al. Silencing of lipocalin‐2 improves cardiomyocyte viability under iron overload conditions via decreasing mitochondrial dysfunction and apoptosis , 2020, Journal of cellular physiology.
[7] S. Stojkovic,et al. Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease , 2020, Disease markers.
[8] C. Andrews,et al. Cannabis in Gastroenterology: Watch Your Head! A Review of Use in Inflammatory Bowel Disease, Functional Gut Disorders, and Gut-Related Adverse Effects , 2020, Current Treatment Options in Gastroenterology.
[9] A. Galli,et al. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? , 2020, Digestive Diseases.
[10] A. Di Paola,et al. The Role of Cannabinoid Receptor Type 2 in the Bone Loss Associated With Pediatric Celiac Disease , 2020, Journal of pediatric gastroenterology and nutrition.
[11] H. Ishikawa,et al. Serum hepcidin level, iron metabolism and osteoporosis in patients with rheumatoid arthritis , 2020, Scientific Reports.
[12] M. Muckenthaler,et al. Disruption of the hepcidin/ferroportin regulatory circuitry causes low axial bone mass in mice. , 2020, Bone.
[13] Margaux J. Barnes,et al. Relations between disease status and body composition in pediatric inflammatory bowel disease , 2020, European Journal of Pediatrics.
[14] ZeGang Ma,et al. JWH133 inhibits MPP+-induced inflammatory response and iron influx in astrocytes , 2020, Neuroscience Letters.
[15] Q. Guan. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease , 2019, Journal of immunology research.
[16] A. Di Paola,et al. The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases , 2019, International journal of molecular sciences.
[17] P. Shang,et al. The Effect of Abnormal Iron Metabolism on Osteoporosis , 2019, Biological Trace Element Research.
[18] Xiaoxu Yang,et al. The Role of Transient Receptor Potential Vanilloid 1 in Common Diseases of the Digestive Tract and the Cardiovascular and Respiratory System , 2019, Front. Physiol..
[19] G. Toro,et al. Bone alterations in inflammatory bowel diseases , 2019, World journal of clinical cases.
[20] H. Salem,et al. A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major , 2019, Drug design, development and therapy.
[21] V. Annese. A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease , 2019, Saudi journal of medicine & medical sciences.
[22] G. A. P. Silva,et al. Linear growth and bone metabolism in pediatric patients with inflammatory bowel disease. , 2019, Jornal de pediatria.
[23] I. Yanatori,et al. DMT1 and iron transport , 2019, Free radical biology & medicine.
[24] N. Rezaei,et al. Early onset inflammatory bowel disease: manifestations, genetics and diagnosis. , 2019, The Turkish journal of pediatrics.
[25] Y. Ginzburg. Hepcidin-ferroportin axis in health and disease. , 2019, Vitamins and hormones.
[26] Peter W. Swaan,et al. Post‐translational modifications of transporters , 2018, Pharmacology & therapeutics.
[27] V. Mihál,et al. Hepcidin in newly diagnosed inflammatory bowel disease in children , 2018, Journal of paediatrics and child health.
[28] L. Cohen,et al. Endocrine Late Effects in Childhood Cancer Survivors. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] N. Chattipakorn,et al. Combined iron chelator and T‐type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron‐overload thalassemic mice , 2018, European journal of pharmacology.
[30] E. Miele,et al. Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease , 2016, Journal of clinical gastroenterology.
[31] I. Shimon,et al. Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[32] B. Cherayil,et al. Iron and inflammation - the gut reaction. , 2017, Metallomics : integrated biometal science.
[33] M. Wessling-Resnick,et al. Regulation of divalent metal transporter-1 by serine phosphorylation , 2016, The Biochemical journal.
[34] S. Saad,et al. A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. , 2016, Blood.
[35] D. Girelli,et al. Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.
[36] W. Hofstetter,et al. Extracellular Iron is a Modulator of the Differentiation of Osteoclast Lineage Cells , 2015, Calcified Tissue International.
[37] S. Saeed,et al. Inflammatory Bowel Disease in Children and Adolescents. , 2021, Advances in pediatrics.
[38] B. Sands. Biomarkers of Inflammation in Inflammatory Bowel Disease. , 2015, Gastroenterology.
[39] L. French,et al. Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort , 2015, Inflammatory bowel diseases.
[40] S. Perrotta,et al. Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels , 2014, Haematologica.
[41] G. Veres,et al. ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.
[42] T. Ganz,et al. Hepcidin Induction by Pathogens and Pathogen-Derived Molecules Is Strongly Dependent on Interleukin-6 , 2013, Infection and Immunity.
[43] J. Isaacs,et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis , 2013, Arthritis Research & Therapy.
[44] K. Papadakis,et al. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. , 2013, Journal of Crohn's & colitis.
[45] S. Maione,et al. The 17-β-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. , 2013, Pharmacological research.
[46] F. Locatelli,et al. Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease , 2012, PloS one.
[47] A. Fasano,et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention. , 2012, Pharmacological research.
[48] C. Hong,et al. The bone morphogenetic protein–hepcidin axis as a therapeutic target in inflammatory bowel disease , 2012, Inflammatory bowel diseases.
[49] S. Perrotta,et al. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy. , 2011, Bone.
[50] L. Petrocellis,et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. , 2009, Bone.
[51] F. Gonzalez,et al. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. , 2009, Cell metabolism.
[52] A. Zimmer,et al. Endocannabinoids and the Regulation of Bone Metabolism , 2008, Journal of neuroendocrinology.
[53] A. Bousvaros,et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation , 2006, Inflammatory bowel diseases.
[54] B. Frenkel,et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[55] N. Khaper,et al. Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy , 2006, Journal of Molecular Medicine.
[56] D. Julius,et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway , 1997, Nature.
[57] G. Roodman,et al. Transcriptional regulation of the tartrate-resistant acid phosphatase (TRAP) gene by iron. , 1994, The Biochemical journal.